Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl亚型特异性产品:Bcr-Abl Isoform Comparison
共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Enzyme modulator-1

Enzyme modulator-1(实施例205)是一种强效酶调节剂,可调控p38、bcr-ab1及VEGFR,可用于癌症、类风湿性关节炎以及包括糖尿病视网膜病变和黄斑变性在内的视网膜疾病的研究。

897375-76-7
Modulator
Enzyme modulator-1

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础